|
Variable
|
Total (cases)
|
Events (cases)
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR (95% CI)
|
P value
|
Estimated coefficient
|
HR (95% CI)
|
P value
|
|---|
|
Age (years)
| | |
0.738 (0.471–1.156)
|
0.233
| | | |
|
< 65
|
281
|
139
| | | | | |
|
≥ 65
|
43
|
17
| | | | | |
|
Sex
| | |
0.966 (0.580–1.609)
|
0.895
| | | |
|
Male
|
285
|
140
| | | | | |
|
Female
|
39
|
16
| | | | | |
|
Hepatitis B surface antigen
| | |
2.070 (1.363–3.146)
|
0.008
|
0.609
|
1.838 (1.016–3.327)
|
0.044
|
|
Yes
|
276
|
142
| | | | | |
|
No
|
48
|
14
| | | | | |
|
Liver macronodular cirrhosis
| | |
1.741 (1.235–2.455)
|
0.006
|
0.125
|
1.133 (0.814–1.575)
|
0.460
|
|
None
|
87
|
33
| | | | | |
|
Light
|
226
|
121
| | | | | |
|
Medium
|
8
|
1
| | | | | |
|
Heavy
|
3
|
1
| | | | | |
|
AFP (ng/mL)
| | |
1.712 (1.242–2.361)
|
< 0.001
|
0.128
|
1.137 (0.793–1.629)
|
0.485
|
|
< 200
|
182
|
74
| | | | | |
|
≥ 200
|
142
|
82
| | | | | |
|
CA19-9 (ng/mL)
| | |
1.359 (0.920–2.009)
|
0.092
| | | |
|
< 35
|
248
|
116
| | | | | |
|
≥ 35
|
76
|
40
| | | | | |
|
AST (IU/L)
| | |
1.930 (1.226–3.039)
|
< 0.001
|
0.122
|
1.129 (0.673–1.895)
|
0.646
|
|
< 50
|
266
|
119
| | | | | |
|
≥ 50
|
58
|
37
| | | | | |
|
ALT (IU/L)
| | |
1.516 (1.039–2.213)
|
0.018
|
0.285
|
1.329 (0.866–2.041)
|
0.193
|
|
< 50
|
246
|
109
| | | | | |
|
≥ 50
|
78
|
47
| | | | | |
|
Hemoglobin (g/L)
| | |
0.733 (0.472–1.140)
|
0.124
| | | |
|
< 130
|
55
|
30
| | | | | |
|
≥ 130
|
269
|
126
| | | | | |
|
Albumin (g/dL)
| | |
0.819 (0.176–3.812)
|
0.778
| | | |
|
< 35
|
5
|
2
| | | | | |
|
≥ 35
|
319
|
154
| | | | | |
|
Bilirubin (mg/dL)
| | |
1.157 (0.770–1.737)
|
0.461
| | | |
|
< 17.1
|
260
|
124
| | | | | |
|
≥ 17.1
|
64
|
32
| | | | | |
|
Platelet count (*103/mm3)
| | |
0.610 (0.250–1.490)
|
0.168
| | | |
|
< 80
|
14
|
8
| | | | | |
|
≥ 80
|
310
|
148
| | | | | |
|
Prothrombin time (INR)
| | |
–
|
0.070
| | | |
|
≤ 0.85
|
3
|
0
| | | | | |
|
0.85–1.2
|
313
|
151
| | | | | |
|
> 1.2
|
8
|
5
| | | | | |
|
HBV-DNA copy number (Log)
| | |
1.183 (0.863–1.621)
|
0.301
| | | |
|
< 2
|
142
|
64
| | | | | |
|
≥ 2
|
182
|
92
| | | | | |
|
Bleeding (mL)
| | |
2.139 (1.090–4.197)
|
0.002
|
0.550
|
1.734 (0.872–3.446)
|
0.117
|
|
< 800
|
299
|
138
| | | | | |
|
≥ 800
|
25
|
18
| | | | | |
|
Operation time (min)
| | |
1.194 (0.769–1.855)
|
0.400
| | | |
|
< 200
|
273
|
129
| | | | | |
|
≥ 200
|
51
|
27
| | | | | |
|
Portal vein embolization
| | |
1.407 (1.000–1.980)
|
0.400
| | | |
|
Yes
|
107
|
59
| | | | | |
|
No
|
217
|
97
| | | | | |
|
Tumor size (cm)
| | |
2.175 (1.570–3.012)
|
< 0.001
|
0.208
|
1.231 (0.809–1.872)
|
0.332
|
|
< 5
|
184
|
69
| | | | | |
|
≥ 5
|
140
|
87
| | | | | |
|
Tumor number
| | |
2.324 (1.592–3.392)
|
< 0.001
|
0.573
|
1.774 (1.223–2.573)
|
0.003
|
|
Single
|
236
|
94
| | | | | |
|
2–3 lesions
|
88
|
62
| | | | | |
|
Cancer cell differentiation
| | |
0.615 (0.446–0.849)
|
0.001
|
− 0.295
|
0.745 (0.535–1.036)
|
0.080
|
|
Low
|
162
|
90
| | | | | |
|
Medium
|
151
|
64
| | | | | |
|
High
|
11
|
2
| | | | | |
|
Tumor thrombus
| | |
4.126 (1.856–9.170)
|
< 0.001
|
0.857
|
2.356 (1.344–4.130)
|
0.003
|
|
Yes
|
29
|
23
| | | | | |
|
No
|
295
|
133
| | | | | |
|
MVI
| | |
2.291 (1.646–3.189)
|
< 0.001
|
0.514
|
1.673 (1.150–2.433)
|
0.007
|
|
Yes
|
136
|
85
| | | | | |
|
No
|
188
|
71
| | | | | |
|
Surgical procedure
| | |
1.108 (0.444–2.764)
|
0.718
| | | |
|
Irregular
|
200
|
97
| | | | | |
|
Regular
|
124
|
59
| | | | | |
|
Tumor encapsulation
| | |
0.978 (0.639–1.498)
|
0.010
|
− 0.079
|
0.924 (0.753–1.135)
|
0.453
|
|
Absent
|
119
|
63
| | | | | |
|
Incomplete
|
79
|
43
| | | | | |
|
Complete
|
126
|
50
| | | | | |
|
Tumor boundary
| | |
2.343 (1.204–4.559)
|
< 0.001
|
− 0.016
|
0.985 (0.535–1.814)
|
0.960
|
|
Clear
|
295
|
136
| | | | | |
|
Unclear
|
29
|
20
| | | | | |
- HR hazard ratio, CI confidence interval, AFP = alpha fetoprotein, CA19-9 carbohydrate antigen 19-9, AST aspartate transaminase, ALT aminotransferase, INR international normalized ratio, HBV hepatitis B virus, MVI microvascular tumor invasion
